CTI BioPharma is a leading brand that specializes in the acquisition, development, and commercialization of targeted therapies for blood-related cancers. Their mission is to provide unique benefits to patients by uncovering the underlying scientific drivers of rare blood-related cancers and developing novel therapies. They offer a range of medicines, including VONJO® (pacritinib), which is approved in the U.

S. CTI BioPharma is actively involved in clinical trials, with their ongoing Phase 3 trial called PACIFICA, where pacritinib is being evaluated compared to physicians' choice therapy for the treatment of myelofibrosis with severe thrombocytopenia. The company measures its success by the impact it has on patients, and they are dedicated to advancing new medicines that can make a difference in patients' lives.

With a strong focus on compliance, transparency, and patient resources, CTI BioPharma is committed to improving the lives of patients with rare blood-related cancers. Join their team and be part of their mission to develop innovative therapies